Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

@article{Jacobson2013SofosbuvirFH,
  title={Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.},
  author={Ira M Jacobson and Stuart C Gordon and Kris V. Kowdley and Eric M Yoshida and Maribel Rodr{\'i}guez-Torres and Mark S. Sulkowski and Mitchell L. Shiffman and Eric Lawitz and Gregory T. Everson and Michael T. Bennett and Eugene R Schiff and M. Tarek Al-Assi and Gangadharan Mani Subramanian and Di An and Ming-hua Lin and John McNally and Diana M. Brainard and William T. Symonds and John McHutchison and Keyur Patel and Jordan J. Feld and Stephen Pianko and David R Nelson},
  journal={The New England journal of medicine},
  year={2013},
  volume={368 20},
  pages={
          1867-77
        }
}
BACKGROUND Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferon treatment, currently have no approved treatment options. In phase 2 trials, regimens including the oral nucleotide polymerase inhibitor sofosbuvir have shown efficacy in patients with HCV genotype 2 or 3 infection. METHODS We conducted two randomized, phase 3 studies involving patients with chronic HCV… 

Figures and Tables from this paper

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
TLDR
Therapy with sofosbuvir-ribavirin for 12 weeks in patients with hepatitis C virus genotype 2 infection and for 24 weeks in Patients with HCV genotype 3 infection resulted in high rates of sustained virologic response.
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
TLDR
Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
TLDR
For treatment-naïve and -experienced patients, ledipasvir-sofosbuvir for 12 weeks is highly effective for the treatment of HCV genotype 2.
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
TLDR
In treatment‐experienced patients with HCV genotypes 2 and 3, 12‐week administration of SOF+Peg‐IFN+RBV provided high SVR rates, irrespective of cirrhosis status, and no safety concerns were identified.
Sofosbuvir-based interferon-free therapy for patients with HCV infection.
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial
TLDR
Twelve weeks of sofosbuvir and ribavirin resulted in high rates of SVR12 in treatment‐naïve and previously treated patients with chronic genotype 2 HCV infection, safe and well tolerated by patients, including the elderly and those with cirrhosis.
Sofosbuvir plus ribavirin as a treatment alternative for chronic HCV genotype 2 or 3 patients unable to benefit from standard therapy.
  • S. Flamm
  • Medicine, Biology
    Gastroenterology & hepatology
  • 2013
TLDR
Two phase 3 trials were designed to evaluate sofosbuvir plus ribavirin specifically in genotype 2 or 3 HCV-infected patients in whom either peginterferon therapy was not an option or who had previously failed to respond to peginerferon.
Hepatitis C Treatment & Management
TLDR
Regimens that include a protease inhibitor significantly improve sustained virologic response rates in patients with genotype 1 HCV infection.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 21 REFERENCES
Sofosbuvir for previously untreated chronic hepatitis C infection.
TLDR
In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
TLDR
Sofosbuvir plus ribavirin for 12 weeks may be effective in previously untreated patients with HCV genotype 1, 2, or 3 infection, and the rate of sustained virologic response 24 weeks after therapy is reported.
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
TLDR
Treatment with peginterferon and ribavirin for 16 weeks in patients infected with HCV genotype 2 or 3 results in a lower overall sustained virologic response rate than treatment with the standard 24-week regimen.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
TLDR
In patients with chronic hepatitis C, initial therapy withinterferon and ribavirin was more effective than treatment with interferon alone.
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
TLDR
Peginterferon alfa-2b plus weight-based ribavirin is effective and safe in patients who failed interferonAlfa/ribavirin therapy andGenotype, baseline viral load, and fibrosis stage were predictors of response.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
TLDR
In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
High sustained virologic response rates in rapid virologic response patients in the large real‐world PROPHESYS cohort confirm results from randomized clinical trials
TLDR
AVR by week 2 or 4 had the highest positive PV for SVR24 and differed according to HCV genotype, while the absence of a VR by week 12 had the high negative PV across all genotypes.
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
TLDR
A comprehensive literature review is provided that systematically describes the adverse effects of Peg-IFN-α and ribavirin on various organ systems and recommends consensus approaches to managing those effects.
Surprisingly Small Effect of Antiviral Treatment in Patients with Hepatitis C
TLDR
The overall antiviral treatment rate and the reasons for nontreatment in a general population of HCV-infected patients in a metropolitan liver clinic are investigated.
Adverse effects of drugs in the treatment of viral hepatitis.
  • F. Negro
  • Medicine, Biology
    Best practice & research. Clinical gastroenterology
  • 2010
...
1
2
3
...